China Expects M&A, Sharper Competition To Result From New Drug Policy
This article was originally published in PharmAsia News
Executive SummaryChina's Health Ministry is looking to its new essential drugs policy to spur drug maker competition, along with the potential for mergers and acquisitions. The head of the ministry's program called the policy the central part of the nation's medical reform plan. He said establishing a competitive bidding process for drug makers to sell to the government means all makers of the same drug are not going to succeed. That means more mergers and acquisitions are likely to result in China, he said. Domestic generics makers are expected to be the major beneficiaries of the new policy. (Click here for more
You may also be interested in...
Novartis has been tipped to regain dominance in AMD, but Bayer/Regeneron have also gained 12-week dosing approval.
Xellia has added a 500mg/100ml variant to its range of vancomycin ready-to-use bags in the US, while Kabi has introduced ertapenem 1g vials and struck a critical-care supply deal with Vizient.